2023年11月2日 · DSP-5336 is an investigational, oral small molecule designed to inhibit the menin and MLL protein interaction. Methods: A Phase 1/2 study of DSP-5336 is being conducted in pts with relapsed or refractory (R/R) acute leukemia.

2023年12月11日 · DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis. 1,2,3

2024年6月14日 · DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in biological pathways, including cell growth regulation, cell cycle control, genomic stability, bone development, and hematopoiesis.1,2,3.

2024年7月15日 · DSP-5336 is an investigational small molecule inhibitor of the menin and mixed-lineage leukemia (MLL) protein interaction, which plays key roles in gene expression and protein interactions involved in many biological pathways, including cell growth, cell cycle, genomic stability, and hematopoiesis.1,2,3.

2024年7月15日 · The FDA has granted DSP-5336 a fast track designation, supported by updated findings from an ongoing phase 1/2 study (NCT04988555). DSP-5336 is an investigational Menin and mixed-lineage leukemia inhibitor.

2024年7月16日 · The FDA has granted fast track designation to the investigational small molecule menin inhibitor DSP-5336 as a treatment for patients with relapsed/refractory acute myeloid leukemia (AML) harboring a KMT2A rearrangement—otherwise known as an mixed lineage leukemia (MLL) rearrangement or NPM1 mutation—according to a press release from the ...

2022年8月3日 · DSP-5336 is an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein.

2021年11月23日 · Results: We generated DSP-5336, a novel, potent, and orally bioavailable MENIN-MLL interaction inhibitor for the treatment of acute leukemia patients with MLL -r or NPM1 mutation. DSP-5336 directly bound to the MENIN protein (Kd = 6.0 nM) and inhibited the MENIN-MLL interaction (IC 50 = 1.4 ± 0.058 nM).

DSP-5336, a novel, investigational oral small-molecule agent, was developed to disrupt binding between menin and mixed-lineage leukemia (MLL/KMT2A) proteins. Nonclinical studies of DSP-5336 showed selective growth inhibition against human acute leukemia cell lines with MLL–rearrangement (r) or nucleophosmin 1 (NPM1) mutation (m).

2022年8月3日 · Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, for the treatment of acute ...